<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="826">
  <stage>Registered</stage>
  <submitdate>10/10/2005</submitdate>
  <approvaldate>13/10/2005</approvaldate>
  <actrnumber>ACTRN12605000636651</actrnumber>
  <trial_identification>
    <studytitle>Phase 1 Study of Coxsackievirus A21 for the treatment of melanoma</studytitle>
    <scientifictitle>Intratumoural administration of coxsackievirus A21 for the control of malignant melanoma.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Malignant Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single intratumoural injection of coxsackievirus A21.</interventions>
    <comparator>uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety profile of treatment</outcome>
      <timepoint>Assessed three times weekly for 2 weeks, then weekly for 2 weeks.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Characterisation of adverse events</outcome>
      <timepoint>Assessed three times weekly for 2 weeks, then weekly for 2 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical response of injected and non-injected tumours.</outcome>
      <timepoint>Assessed weekly for 4 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stage IV melanoma (AJCC)- minimum of 2 SC metastases- failure or refusal of standard chemotherapy- ECOG score of 0 or 1- other.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Metastatic CNS disease- occular or mucosal melanoma- immunodeficiency- splenectomy- other.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/09/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>3</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Viralytics Ltd.</primarysponsorname>
    <primarysponsoraddress>8/33 Ryde Rd., Pymble, NSW 2073</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Viralytics Ltd.</fundingname>
      <fundingaddress>8/33 Ryde Rd., Pymble, NSW 2073</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Phillip Altman</name>
      <address>8/33 Ryde Rd., Pymble, NSW 2073</address>
      <phone>+61(2)94993200</phone>
      <fax>+61(2)94993300</fax>
      <email>pmaltman@bigpond.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Phillip Altman</name>
      <address>Melanoma Unit
Mater Misericordiae Hospital
Newcastle NSW 2298</address>
      <phone>+61 2 49850100</phone>
      <fax />
      <email>Peter.Hersey@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>